Moderna (MRNA) Net Margin: 2017-2025
Historic Net Margin for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -19.69%.
- Moderna's Net Margin fell 2038.00% to -19.69% in Q3 2025 from the same period last year, while for Sep 2025 it was -139.61%, marking a year-over-year decrease of 9527.00%. This contributed to the annual value of -110.04% for FY2024, which is 4121.00% down from last year.
- According to the latest figures from Q3 2025, Moderna's Net Margin is -19.69%, which was up 96.61% from -580.99% recorded in Q2 2025.
- Moderna's Net Margin's 5-year high stood at 67.51% during Q4 2021, with a 5-year trough of -899.07% in Q1 2025.
- Its 3-year average for Net Margin is -330.25%, with a median of -198.25% in 2023.
- In the last 5 years, Moderna's Net Margin surged by 161,304bps in 2021 and then plummeted by 70,784bps in 2024.
- Quarterly analysis of 5 years shows Moderna's Net Margin stood at 67.51% in 2021, then crashed by 3,869bps to 28.82% in 2022, then slumped by 2,110bps to 7.72% in 2023, then plummeted by 12,366bps to -115.94% in 2024, then crashed by 2,038bps to -19.69% in 2025.
- Its Net Margin stands at -19.69% for Q3 2025, versus -580.99% for Q2 2025 and -899.07% for Q1 2025.